LLY · 10-Q · 2026Q2 · Full report

Regulatory Approval - Foundayo

ELI LILLY & Co · 2026-08-05 · Importance 44 · Surprise 60

The FDA approved orforglipron, marketed as Foundayo, for treatment of obesity. Lilly launched Foundayo in the U.S. during the second quarter of 2026 and submitted it to the FDA for type 2 diabetes. The company also submitted orforglipron for type 2 diabetes in the U.S., EU, and Japan and expects additional regulatory approvals to influence near-term performance.

Key facts

• The FDA approved orforglipron (Foundayo) for treatment of obesity. source